Anti-LDL Receptor

LDL receptor (LDLR) is a cell surface glycoprotein that scavenges LDL from the blood and regulates plasma LDL levels. It is composed of an N-terminal signal sequence, a ligand-binding domain, an EGF precursor homology domain, an O-linked glycosylation domain, a transmembrane region, and a C-terminal cytoplasmic tail. LDLR is primarily expressed in the liver but is also found in the adrenal cortex. It mediates the endocytosis of LDL by binding to apolipoprotein E (ApoE) or ApoB on the LDL surface, thereby supplying cholesterol to cells. Protein levels of LDLR are decreased in HepG2 cells expressing proprotein convertase subtilisin kexin 9 (PCSK9). Knockout of Ldlr increases plasma levels of cholesterol and triglycerides and induces the formation of atherosclerotic lesions in mice. Mutations in LDLR are associated with familial hypercholesterolemia. Cayman's LDL Receptor Polyclonal Antibody can be used for immunocytochemistry (ICC), immunohistochemistry (IHC), and Western blot (WB) applications.Synonyms: LDLR, Low Density Lipoprotein Receptor. Immunogen: Synthetic peptide from the C-terminal region of mouse LDL Receptor. Formulation: (Request formulation change), 500 µl of peptide affinity-purified polyclonal antibody. Storage Buffer: PBS, pH 7.2, with 50% glycerol and 0.02% sodium azide. Host: Rabbit. Applications: ICC, IHC, and WB. UniProt Accession #: P35951. Origin: Animal/Rabbit.